[go: up one dir, main page]

DE69929612D1 - Purifikation von viruspräparaten - Google Patents

Purifikation von viruspräparaten

Info

Publication number
DE69929612D1
DE69929612D1 DE69929612T DE69929612T DE69929612D1 DE 69929612 D1 DE69929612 D1 DE 69929612D1 DE 69929612 T DE69929612 T DE 69929612T DE 69929612 T DE69929612 T DE 69929612T DE 69929612 D1 DE69929612 D1 DE 69929612D1
Authority
DE
Germany
Prior art keywords
purification
groups
virus preparations
polysacharide
sulfated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69929612T
Other languages
English (en)
Other versions
DE69929612T2 (de
Inventor
Denis Johnston
Simon O'keeffe
Kenneth Slater
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Pharmaceuticals Research Ltd
Original Assignee
Cantab Pharmaceuticals Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Research Ltd filed Critical Cantab Pharmaceuticals Research Ltd
Publication of DE69929612D1 publication Critical patent/DE69929612D1/de
Application granted granted Critical
Publication of DE69929612T2 publication Critical patent/DE69929612T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69929612T 1998-03-05 1999-03-05 Purifikation von viruspräparaten Expired - Lifetime DE69929612T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9804632 1998-03-05
GBGB9804632.9A GB9804632D0 (en) 1998-03-05 1998-03-05 Virus preparations and methods
PCT/GB1999/000669 WO1999045104A2 (en) 1998-03-05 1999-03-05 Purification of virus preparations

Publications (2)

Publication Number Publication Date
DE69929612D1 true DE69929612D1 (de) 2006-04-13
DE69929612T2 DE69929612T2 (de) 2006-11-02

Family

ID=10827994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929612T Expired - Lifetime DE69929612T2 (de) 1998-03-05 1999-03-05 Purifikation von viruspräparaten

Country Status (13)

Country Link
US (1) US6267967B1 (de)
EP (1) EP1062325B1 (de)
JP (1) JP2002505101A (de)
AT (1) ATE316571T1 (de)
AU (1) AU3266599A (de)
BR (1) BR9908424A (de)
CA (1) CA2322615A1 (de)
DE (1) DE69929612T2 (de)
DK (1) DK1062325T3 (de)
ES (1) ES2257867T3 (de)
GB (1) GB9804632D0 (de)
PT (1) PT1062325E (de)
WO (1) WO1999045104A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
JP4790984B2 (ja) * 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
WO2003093463A1 (en) 2002-04-30 2003-11-13 Oncolytics Biotech Inc. Improved viral purification methods
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
DK3246399T3 (da) * 2002-12-13 2021-10-04 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling
DK1608762T3 (da) * 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
DE602004028736D1 (de) * 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
ES2327643T3 (es) * 2003-07-11 2009-11-02 Alphavax, Inc. Vacunas contra citomegalovirus basadas en alfavirus.
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
JP2008512443A (ja) * 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
MX344592B (es) * 2005-12-13 2016-12-20 Exthera Medical Corp Metodo para eliminar extracorporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
AU2008250596C1 (en) * 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
JP5602624B2 (ja) * 2007-06-21 2014-10-08 アルファバックス， インコーポレイテッド αウイルス構造タンパク質の発現のためのプロモーターレスカセット
WO2010019572A1 (en) * 2008-08-11 2010-02-18 Sanofi Pasteur Biologics Co. Compositions and methods for the production of alpha-herpesviruses
EP2509604B1 (de) 2009-12-01 2021-03-17 ExThera Medical Corporation Vorrichtung zur beseitigung von zytokinen aus blut mit oberflächenimmobilisierten polysacchariden
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
US9879229B2 (en) 2011-03-14 2018-01-30 National Research Council Of Canada Method of viral production in cells
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
EP2852662B1 (de) 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesviruszusammensetzungen und zugehörige verfahren
EP2861273B1 (de) 2012-06-13 2017-08-23 ExThera Medical Corporation Verwendung von heparin und kohlenhydraten zur behandlung von krebs
HK1216625A1 (zh) 2013-06-24 2016-11-25 Exthera Medical Corporation 含有塗覆甘露糖的基質的血液過濾系統
AU2014346668C1 (en) 2013-11-08 2018-04-26 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
EP3134146B1 (de) 2014-04-24 2024-12-25 ExThera Medical Corporation Verfahren zur entfernung von bakterien aus blut unter verwendung einer hohen durchflussrate
CN106714669B (zh) 2014-09-22 2021-05-14 艾克塞拉医疗公司 可穿戴的血液灌流装置
EP3422943A4 (de) 2016-03-02 2019-10-16 ExThera Medical Corporation Verfahren zur behandlung von arzneimittelintoxikation
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
EP3969014A4 (de) 2019-05-16 2023-01-25 ExThera Medical Corporation Verfahren zur modulation der endothelialen glycocalyxstruktur

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209738C (de)
JPS5341202B2 (de) 1974-03-12 1978-11-01
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
GB2080682B (en) * 1980-07-30 1984-03-28 Ciba Geigy Ag Antiherpetically active lipstick
US4515714A (en) * 1983-03-09 1985-05-07 Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute Method for purification of hepatitis B virus surface antigen
JPS6153226A (ja) * 1984-08-24 1986-03-17 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニツトワクチンの精製方法
US5024836A (en) 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
ATE194657T1 (de) 1990-09-25 2000-07-15 Cantab Pharma Res Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
JPH06234659A (ja) 1992-05-05 1994-08-23 Handai Biseibutsubiyou Kenkyukai 安定化生ワクチン
WO1993024616A1 (en) 1992-06-04 1993-12-09 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
US5360736A (en) 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
EP0689603A1 (de) 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff
US5447859A (en) * 1993-07-16 1995-09-05 Viagene Method for the purification or removal of retroviruses using sulfated cellulose

Also Published As

Publication number Publication date
CA2322615A1 (en) 1999-09-10
PT1062325E (pt) 2006-05-31
AU3266599A (en) 1999-09-20
WO1999045104A3 (en) 1999-11-04
DE69929612T2 (de) 2006-11-02
BR9908424A (pt) 2000-10-31
DK1062325T3 (da) 2006-05-15
EP1062325A2 (de) 2000-12-27
ATE316571T1 (de) 2006-02-15
US6267967B1 (en) 2001-07-31
WO1999045104A2 (en) 1999-09-10
GB9804632D0 (en) 1998-04-29
JP2002505101A (ja) 2002-02-19
EP1062325B1 (de) 2006-01-25
ES2257867T3 (es) 2006-08-01

Similar Documents

Publication Publication Date Title
ATE316571T1 (de) Purifikation von viruspräparaten
HUP9900920A2 (hu) Eljárás emlőssejt-tenyészetekben termelt proteinek szializációjának szabályozására
EP0570916A3 (de) Menschliches rekombinantes Serum-Albumin, Verfahren zur dessen Herstellung und diese enthaltende pharmazeutischen Präparate.
AU4052389A (en) Derivatized glass supports for peptide and protein sequencing
AU7489687A (en) Translation of mrna
EP0670369A3 (de) An menschliches programmiertes Zelltod relatiertes Peptid, und dessen kodierende DNA
BR9915940A (pt) Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
ES2183133T3 (es) Composiciones de lipidos.
NL300249I2 (en) Cephalosporins and homologues, preparations and pharmaceutical preparations.
CA2169834A1 (en) Pharmaceutical formulations of nerve growth factor
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
FR2738151B1 (fr) Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
EP0754229A1 (de) Afamin: ein menschliches serum albumin ähnliches protein
FI72143C (fi) Foerfarande foer framstaellning av maenniskointerferon.
DE69023648D1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
DE3884680D1 (de) Äusseres Membranprotein F von Pseudomonas aeruginosa.
DE69940692D1 (de) Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
EP0373540A3 (de) Verfahren zur Reinigung des Fibroblast-Wachstumsfaktor-Proteins
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
ES2052883T3 (es) Cultivo de celulas de riñon de cerdo y su uso en la produccion de vacunas.
DE59107762D1 (de) Komplexe, enthaltend S(+)-Phenyl-alkansäuren und alpha-Hydroxy-alkansäuren
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition